Want to see PDEX full AI Analyst Report?
Top Page
Pro-Dex
(NASDAQ:PDEX)
Select Model
Select Model
Rating:75Outperform
Price Target:
$71.00
▲(93.14% Upside)
Action:Reiterated
Date:05/21/26
The score is driven primarily by solid financial performance with strong recent margins and improving leverage, tempered by inconsistent operating cash-flow conversion. Technicals add support due to a clear uptrend, though overbought signals increase near-term risk. Valuation contributes positively given the low P/E.
Positive Factors
Sustained Profitability
Consistent TTM margins near these levels indicate durable pricing power and manufacturing efficiency in precision surgical devices. High margins support internal R&D and capital allocation, improving resilience to cycle swings and enabling reinvestment for long-term product and process improvements.
Negative Factors
Inconsistent Operating Cash Flow
Volatile operating cash conversion implies working-capital and timing risk tied to project billing and production cycles. This undermines predictability for capex, dividends, or debt service, raising financing and execution risk over the 2–6 month horizon and complicating long-term planning.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Profitability
Consistent TTM margins near these levels indicate durable pricing power and manufacturing efficiency in precision surgical devices. High margins support internal R&D and capital allocation, improving resilience to cycle swings and enabling reinvestment for long-term product and process improvements.
Read all positive factors
Pro-Dex Key Performance Indicators (KPIs)
Any
Revenue by Segment
Highlights revenue from different business segments, revealing which areas are driving growth and which may need strategic adjustments.
Highlights revenue from different business segments, revealing which areas are driving growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyPro-Dex (PDEX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$188.63M
Dividend YieldN/A
Average Volume (3M)29.60K
Price to Earnings (P/E)16.0
Beta (1Y)0.27
Revenue Growth16.39%
EPS Growth29.86%
CountryUS
Employees181
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)3.70
Shares Outstanding3,192,759
10 Day Avg. Volume32,852
30 Day Avg. Volume29,604
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)3.92
Price to Sales (P/S)2.15
P/FCF Ratio-49.00
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$70.00Price Target Upside90.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pro-Dex Business Overview & Revenue Model
Company Description
Pro-Dex, Inc. focuses on the development and manufacturing of advanced motorized surgical instruments. These sophisticated tools are supplied globally to original equipment manufacturers (OEMs) in the medical device sector. Their product portfolio...
How the Company Makes Money
Pro-Dex makes money primarily by providing contract design, development, and manufacturing services for medical device customers, with revenue recognized from the sale of finished powered surgical instruments, instrument systems, and related parts...
Pro-Dex Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
61
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 74.64M | 66.59M | 53.84M | 46.09M | 42.04M | 42.04M |
| Gross Profit | 20.73M | 19.51M | 14.55M | 12.75M | 13.13M | 13.13M |
| EBITDA | 19.63M | 14.13M | 4.35M | 10.82M | 6.88M | 6.88M |
| Net Income | 12.00M | 8.98M | 2.13M | 7.07M | 4.57M | 4.57M |
Balance Sheet | ||||||
| Total Assets | 74.98M | 61.19M | 52.48M | 51.82M | 49.09M | 49.09M |
| Cash, Cash Equivalents and Short-Term Investments | 10.98M | 7.16M | 6.85M | 4.07M | 1.60M | 1.60M |
| Total Debt | 20.17M | 16.58M | 13.55M | 14.79M | 15.97M | 15.97M |
| Total Liabilities | 29.78M | 24.56M | 21.61M | 20.23M | 23.66M | 23.66M |
| Stockholders Equity | 45.20M | 36.63M | 30.87M | 31.59M | 25.43M | 25.43M |
Cash Flow | ||||||
| Free Cash Flow | 6.97M | -2.93M | 5.22M | 4.49M | -2.52M | -2.52M |
| Operating Cash Flow | 7.34M | -1.68M | 6.20M | 5.46M | -847.00K | -847.00K |
| Investing Cash Flow | 2.72M | -238.00K | -2.23M | -885.00K | -1.24M | -1.24M |
| Financing Cash Flow | -11.23M | -292.00K | -4.27M | -2.49M | -790.00K | -790.00K |
Pro-Dex Technical Analysis
Neutral
36.76
Price Trends
61.85
Negative
55.49
Positive
45.97
Positive
Market Momentum
-0.96
Positive
42.82
Neutral
27.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PDEX, the sentiment is Neutral. The current price of 36.76 is below the 20-day moving average (MA) of 61.14, below the 50-day MA of 61.85, and below the 200-day MA of 45.97, indicating a neutral trend. The MACD of -0.96 indicates Positive momentum. The RSI at 42.82 is Neutral, neither overbought nor oversold. The STOCH value of 27.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PDEX.
Pro-Dex Risk Analysis
Pro-Dex disclosed 24 risk factors in its most recent earnings report. Pro-Dex reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pro-Dex Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $188.63M | 15.97 | 29.10% | ― | 16.39% | 29.86% | |
72 Outperform | $228.42M | 21.74 | 9.13% | 2.15% | -4.43% | -10.66% | |
52 Neutral | $194.76M | -86.18 | -13.61% | ― | 23.30% | 57.37% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
PDEX
Pro-Dex
57.38
11.19
24.23%
UTMD
Utah Medical Products
69.80
15.37
28.23%
MBOT
Microbot Medical
1.75
-0.72
-29.15%
KRMD
REPRO-MED Systems
4.11
0.74
21.96%
ZJYL
Jin Medical International Ltd.
1.90
-11.30
-85.60%
Pro-Dex Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Pro-Dex Issues Updated Investor Presentation Under Regulation FD
Neutral
Jun 17, 2026
On June 17, 2026, Pro-Dex, Inc. began delivering an investor presentation to analysts and institutional investors, aligning the materials with its existing SEC filings and prior public disclosures. The presentation, which may be updated or modifie...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.